By Andrea Park
In an interview with Fierce Medtech during the ADA's scientific sessions, the chief medical officer of Medtronic’s diabetes business, Robert Vigersky, described how the company is looking to completely close the loop on insulin delivery.
read more
By Angus Liu
A new era of breast cancer treatment may be upon us. With a landmark clinical trial win, AstraZeneca and Daiichi Sankyo could soon open up a brand-new breast cancer category and offer HER2-targeted therapy for many patients with what’s been traditionally characterized as HER2-negative disease.
read more
By Gabrielle Masson
The numbers as they stand now don’t lie: Amgen’s Lumakras lasted longer than Mirati’s adagrasib in KRAS-mutated lung cancer. But Mirati's CEO still has high hopes for adagrasib, as an investigator of a study into the latecomer drug told Fierce Biotech that the two therapies have shown "essentially identical" efficacy.
read more
By Annalee Armstrong
Merus’ NRG1 gene targeting cancer treatment helped to shrink tumors and kept working for up to 9.1 months, leaving the company’s leadership with an important question: partner up or go it alone for commercialization?
read more
By Angus Liu
With AstraZeneca and Daiichi Sankyo’s practice-changing clinical data for Enhertu in a new breast cancer category called HER2-low, experts have raised the necessity of revolutionizing how the HER2 biomarker should be measured by diagnostic tests.
read more
By Kevin Dunleavy
Amarin is signaling defeat in its attempts to keep its heart-helping drug Vascepa viable against generic competition in the United States. On Monday, the Dublin-based company revealed it will slash its workforce in the U.S. by 65% in a restructuring plan.
read more
By Susan Kreimer
U.S. physicians rank healthcare access, substance abuse and racial disparities as the leading social issues facing the country, followed closely by gun control and climate change, according to a new survey
read more
By Nick Paul Taylor
Yumanity Therapeutics has struck two agreements to erase itself from existence. Johnson & Johnson has stepped in to take on Yumanity’s lead program and unpartnered discovery-stage candidates, while Kineta has laid claim to its Nasdaq listing and Merck collaboration through a reverse merger.
read more
By Conor Hale
The big medtech signed up to buy Parata Systems from its corporate owner Frazier Healthcare Partners through an all-cash deal expected to close before next March.
read more
By Fraiser Kansteiner
Pfizer on Monday said it’s plugging $120 million into its Kalamazoo, Michigan, plant—the Big Pharma’s largest manufacturing facility—to bolster production of its oral COVID-19 antiviral Paxlovid, also known as nirmatrelvir and ritonavir tablets.
read more
By Heather Landi
Private equity firm Bain Capital snapped up software company LeanTaaS to gain a foothold in the healthcare AI and automation space. The deal also included a "significant" capital investment to help fuel the company's growth.
read more
By Max Bayer
Biogen is looking to fortify the back end of its pipeline, betting more than $700 million on Alectos' preclinical oral Parkinson's med. The two companies will partner on the development of the asset until it's ready for the clinic, at which point Biogen will take the reins.
read more
By Andrea Park
2022 is the year of the Omnipod 5 for Insulet. The year kicked off with FDA clearance for the latest generation of the insulin pump, and the company has spent the ensuing months building out the system’s platform and making it available to more users than ever before.
read more
By Paige Minemyer
Specialty pharmacy is a huge cost concern in the industry, and a new study suggests that using a medically-integrated dispensing model could yield significant savings.
read more
